Both nutrients exert antidepressant effects through gut microbiota regulation, either by enhancing SCFA production or reducing inflammation, making them the most promising candidates for clinical translation (consistent with Sections 4.3, 5.3)
Key Takeaways Foundayo (orforglipron) is the first oral GLP-1 receptor agonist that can be taken any time of day without food or water restrictions FDA approved April 1, 2026 for chronic weight management Average weight loss in the ATTAIN-1 trial was 11.2% at 72 weeks at the highest dose less than injectable Wegovy (14.9%) or Zepbound (20.2%) Its small-molecule structure allows consistent absorption regardless of what is in the stomach Side effect profile is similar to other GLP-1 medications primarily gastrointestinal Starting cost is approximately $25/month with commercial insurance + Lilly savings card, $149/month self-pay for the lowest dose Best suited for patients with needle aversion, complicated schedules, or those who struggled with oral Wegovys fasting requirements Not recommended for patients already responding well to injectable GLP-1s Cannot be combined with other GLP-1 medications References Eli Lilly and Company
The product is also milk, egg, fish, shellfish, tree nut, peanut, wheat, soy, artificial color, sweetener, and preservative-free, making it safe for sensitive digestive systems
at this dose, tirzeaptide drives ~8.3% weight loss compared to 6.6% for semaglutide over 40 weeks in the head-to-head SURPASS-2 trial in patients with obesity and T2D
This gives the HA extra water to grab onto, maximizing that plumping effect
/assets/images/provider/photos/2813769.png)
